Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
Status:
Not yet recruiting
Trial end date:
2022-06-20
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label study where all patients will receive a single injection of
SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the
individual participant is approximately 31 days.